[
  {
    "ts": null,
    "headline": "Regeneron declines to make higher bid for 23andMe after Wojcicki's $305 million offer",
    "summary": "-Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on Monday.  Co-founder Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron's offer for the DNA-testing company in a bankruptcy auction.",
    "url": "https://finnhub.io/api/news?id=304f3dc82a045015e2b27f13b53510db10c2093cd16d1c45069971548d8fc77b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750108973,
      "headline": "Regeneron declines to make higher bid for 23andMe after Wojcicki's $305 million offer",
      "id": 135311929,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "-Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on Monday.  Co-founder Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron's offer for the DNA-testing company in a bankruptcy auction.",
      "url": "https://finnhub.io/api/news?id=304f3dc82a045015e2b27f13b53510db10c2093cd16d1c45069971548d8fc77b"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors",
    "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=bcc993661b6eeab504270d43b16b82c04b9ba80e7807748be51489e5f13410bb",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750092420,
      "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors",
      "id": 135432292,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=bcc993661b6eeab504270d43b16b82c04b9ba80e7807748be51489e5f13410bb"
    }
  },
  {
    "ts": null,
    "headline": "EHA 2025: Regeneron’s Lynozyfic with Amgen’s Kyprolis combo emerges for R/R MM",
    "summary": "Lynozyfic’s global sales are projected to reach $707 million by 2031.",
    "url": "https://finnhub.io/api/news?id=462c3debc4a0ab7694021ac22831712b8a22ad338f9529618750b0b797bad9af",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750070215,
      "headline": "EHA 2025: Regeneron’s Lynozyfic with Amgen’s Kyprolis combo emerges for R/R MM",
      "id": 135303052,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Lynozyfic’s global sales are projected to reach $707 million by 2031.",
      "url": "https://finnhub.io/api/news?id=462c3debc4a0ab7694021ac22831712b8a22ad338f9529618750b0b797bad9af"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Loses Bid as 23andMe to Sell Core Assets to TTAM for $305 Million",
    "summary": "Regeneron Pharmaceuticals (REGN) was edged out in a final bidding round as 23andMe Holding agreed to",
    "url": "https://finnhub.io/api/news?id=aeb42f86bed6d80ad93f0332d65c515fa4ef4e3aa130b7d8ddd78a8bf8e971f2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750069153,
      "headline": "Regeneron Pharmaceuticals Loses Bid as 23andMe to Sell Core Assets to TTAM for $305 Million",
      "id": 135303310,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals (REGN) was edged out in a final bidding round as 23andMe Holding agreed to",
      "url": "https://finnhub.io/api/news?id=aeb42f86bed6d80ad93f0332d65c515fa4ef4e3aa130b7d8ddd78a8bf8e971f2"
    }
  },
  {
    "ts": null,
    "headline": "Kiniksa Pharmaceuticals: Arcalyst Performs, KPL-387 Advancing Fast",
    "summary": "Kiniksa Pharmaceuticals sees strong growth from Arcalyst, aided by Medicare redesign. Learn about 2025 sales outlook & upcoming drug developments.",
    "url": "https://finnhub.io/api/news?id=659479a489ecbde52372c80d9f0b4642c32e1561c0362868535ec0ce5dc83bbf",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750061728,
      "headline": "Kiniksa Pharmaceuticals: Arcalyst Performs, KPL-387 Advancing Fast",
      "id": 135300137,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1445112461/image_1445112461.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Kiniksa Pharmaceuticals sees strong growth from Arcalyst, aided by Medicare redesign. Learn about 2025 sales outlook & upcoming drug developments.",
      "url": "https://finnhub.io/api/news?id=659479a489ecbde52372c80d9f0b4642c32e1561c0362868535ec0ce5dc83bbf"
    }
  }
]